Generic drug maker Amphastar Pharmaceuticals sets terms for $81 million IPO

Comment

Shutterstock photo

Amphastar Pharmaceuticals, which produces difficult-to-manufacture injectable and inhalable drugs, announced terms for its IPO on Friday. The Rancho Cucamonga, CA-based company plans to raise $81 million by offering 7.4 million shares (46% insider) at a price range of $10 to $12. At the midpoint of the proposed range, it would command a fully diluted market value of $475 million. 

Amphastar Pharmaceuticals, which was founded in 1996 and booked $223 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol AMPH. Amphastar initially filed confidentially on December 16, 2013. Jefferies, BMO Capital Markets and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week  of June 23, 2014.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com